Intellectual Property

Threading the biosimilar needle

Thursday, February 11, 2016 @ 7:00 PM | By Nikolas Purcell and Geoffrey Mowatt

Biosimilars, otherwise known as subsequent entry biologics or “SEBs” in Canada, are a rapidly emerging trend in health care.

Biosimilars present novel and intriguing legal issues that are quickly rising to...

To view the full article, Click Here to Subscribe
or sign up for a 14-day FREE Trial

Already a subscriber? Click here to sign in

Featured

COVID-19 UPDATES

Latest

Other Areas of Practice Diversity, inclusion and equity in South Asian legal community | Shreeya Devnani

Civil Litigation Saskatchewan court to offer binding civil, family pretrials

Other Areas of Practice Forensic engineering firm opens Toronto office

Business WeirFoulds adds six new associates

Indigenous Schools Canada failing Indigenous schools during COVID-19 | Maggie Wente